Latest Content
Improvement of Broadly HIV-Neutralizing Antibodies - Anti-HIV-1 Antibody VRC01.23 for Prevention or Treatment of HIV Infection: Licensing and Collaboration Opportunity
Scientists at NIAID have developed broadly neutralizing antibodies (bNAbs) with enhanced neutralizing activity against HIV-1. The new antibodies show improved binding with CD4 by interacting with both binding sites and as a result show improved neutralization of various HIV-1 strains.
Floxed Targeted Mouse Strain with Conditional Deletion of the Irf8 Gene: Collaborative and Licensing Opportunity
The Irf8 floxed mouse strain can be used to selectively ablate expression of IRF8 in any cell type in which a Cre recombinase gene is activated. This will permit the identification of IRF8-regulated genes and their effects in specific types of developing and mature cells.
A High-Yield Perfusion-Based Transient Gene Expression Bioprocess: Licensing Opportunity
Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) developed a new transient gene expression (TGE) bioprocess using a perfusion system that resolves the current fed-batch limitations for influenza vaccine production.
Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof: Licensing Opportunity
Researchers at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) have designed influenza vaccine candidates based on group 2 influenza hemagglutinin (HA) proteins.
Glycan-masked Engineered Outer Domains of HIV-1 GP120 and Their Use: Collaborative and Licensing Opportunity
Newly invented glycan-masked eOD-GT8 60mer mutants may serve as improved priming immunogens to elicit VRC01-class bnAbs in humans.
Using BioPharma Dealmakers
All about how to get the most from the BioPharma Dealmakers website, whether you are a sponsoring Company or a Member.
Follow us on Twitter
BioPharma Dealmakers has just joined Twitter. Follow us for details of our latest content and partnering news stories.
CNS
The latest from BioPharma Dealmakers on companies, research and deals in the CNS field.
Drug Development
The latest from BioPharma Dealmakers on companies, research and deals in the drug development field.
Academic/Non-profit organisation
The latest from BioPharma Dealmakers on establishments, research and deals from academic and non-profit organisations.
Oncology
The latest from BioPharma Dealmakers on companies, research and deals in the oncology field.
Gastrointestinal
The latest from BioPharma Dealmakers on companies, research and deals in the gastrointestinal field.
Dermatology
The latest from BioPharma Dealmakers on companies, research and deals in the dermatology field.
